logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
Y

Yimin Cui

Peking University First Hospital
H指数:41
被引数:7,979

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Author Correction: Lysosomal “TRAP”: a neotype modality for clearance of viruses and variants

作者更正：溶酶体“TRAP”：一种清除病毒和变体的新型模式

Nature Communications
IF15.7
2026-09-210
OAAI
Chengliang Lyu; Zhanlong He; Xiaoming Hu; Shuang Wang; Meng Qin; Li Zhu; Yanyan Li; Fengmei Yang; Zhouguang Jiao; Xiao Zhang; Guihong Lu; Erqiang Wang; Yaling Hu; Yu Zhai; Youchun Wang; Weijin Huang; Dongshu Wang; Yimin Cui; Xiaocong Pang; Xiangzheng Liu; Hidehiro Kamiya; Guanghui Ma; Wei Wei
Urea transporter B–mediated urea uptake–induced protein carbamylation in platelets underlies bleeding in chronic kidney disease

尿毒症转运蛋白B介导的血小板尿素摄取诱导的蛋白质卡巴酰化是慢性肾病出血的基础

Science Translational Medicine
IF14.6
2026-08-190
PRE
Zhiwei Qiu; Fei Xiong; Zhe Wang; Yingxin Zhao; Shuang Gao; Xin Zhang; Yu Chen; Zhiyan Liu; Ruofei Li; Linyu Cao; Lan Sun; Guangying Shao; Tianze Sun; Tao Jiang; Min Li; Jie Dong; Baoxue Yang; Yimin Cui; Qian Xiang
An orally bioavailable pan-αv/α5β1 integrin antagonist prevents aggressive prostate cancer progression via suppressing both oncogenic signals and CD47-mediated immune escape

一种具有口服生物利用度的泛-αv/α5β1整合素拮抗剂通过抑制癌基因信号和CD47介导的免疫逃逸来阻止侵袭性前列腺癌的进展

Molecular Cancer
IF33.9
2026-05-130
OAAI
Yanlun Gu; Bingqi Dong; Xia Teng; Lin Chen; Yang Yang; Xiaojiao Sun; Song Song; Binzhi Qian; Yufang Sun; Jixin Zhang; Zhigang Zheng; Yuke Chen; Yimin Cui; Zhuona Rong; Xiaocong Pang
A multi-dimensional comparative study of 505(b)(2) NDAs approved by FDA and Class 2 NDAs approved by NMPA from 2017 to 2023: Uncovering trends, characteristics, and regulation of modified new drugs

2017年至2023年FDA批准的505(b)(2)新药申请（NDA）与NMPA批准的II类新药申请（NDA）的多维度比较研究：揭示改良型新药的趋势、特征及监管。

Regulatory Toxicology and Pharmacology
IF3.5
2025-05-270
PREAI
Lixia Fu; Songtao Dong; Ran Xie; Guoshu Jia; Nan Zhao; Qian Xiang; Xiwei Ji; Xia Zhao; Xiaoyuan Chen; Lingyue Ma; Yimin Cui
Pharmacokinetics, pharmacodynamics and safety profile of SKB336, a selective inhibitor of coagulation factor XI/XIa in healthy subjects

SKB336的药代动力学、药效动力学及安全性特征，该药物是一种凝血因子XI/XIa的选择性抑制剂，在健康受试者中研究。

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
IF3
2025-04-090
PRE
Xiang, Qian; Liu, Zhiyan; Xie, Qiufen; Zhao, Nan; Zhou, Shuang; Cao, Linyu; Zhao, Xia; Li, Yaling; Si, Jing; Wu, Qingmei; Ge, Junyou; Cui, Yimin
Sustained immunogenicity of bivalent protein COVID-19 vaccine SCTV01C against antigen matched and mismatched variants

双价蛋白COVID-19疫苗SCTV01C对抗原匹配和不匹配变体的持续免疫原性

EXPERT REVIEW OF VACCINES
IF4.8
2025-01-270
OA
Wang, Guiqiang; Zhao, Kexin; Zhao, Xiuli; Cui, Yimin; He, Peng; Zhang, Tianzuo; Wang, Yanchao; Shi, Rui; Li, Yanhua; Wang, Qian; Ren, Yanping; Chen, Zhisong; Zhao, Xuedan; Xie, Zekang; Liang, Yufei; Tian, Qingyun; Pan, Jing; Zhang, Chao; Han, Ying; Dai, Yuyang; Ni, Siyang; Zhang, Yun; Yang, Xinjie; Fu, Yongpan; Liu, Dongfang; Li, Jing; Zhang, Miaomiao; Hu, Zhongyu; Xie, Liangzhi

研究方向

暂未获取到该数据
Q
Qian Xiang
H 指数:57论文数:726被引数:1.4万
Y
Yunlong Tan
H 指数:43论文数:338被引数:8,754
G
Guangyan Mu
H 指数:13论文数:66被引数:634
霍
霍勇
H 指数:62论文数:868被引数:1.9万
Z
Zhiren Wang
H 指数:33论文数:265被引数:5,525
Z
Zhiyan Liu
H 指数:37论文数:342被引数:5,220
X
Xia Zhao
H 指数:46论文数:258被引数:6,485
L
L. Elliot Hong
H 指数:57论文数:322被引数:1.2万
X
Xianhui Qin
H 指数:43论文数:534被引数:7,439
Q
Qiufen Xie
H 指数:12论文数:80被引数:589